After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal
NICE Rejected Real World Data
Executive SummaryTagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.
You may also be interested in...
“Growth gaps” were the driver for a record-breaking M&A year – but CEOs must remain disciplined when pursuing opportunities, or pay the price down the line.
Companies continue to throw their hats into the ring against the virus, with strategies ranging from ‘off the shelf’ molecules to novel vaccine and anti-viral therapies